Table 1 Institutional data
From: High-grade astrocytoma with piloid features: a single-institution case series and literature review
Patient | Age/ Sex1 | Pathology | Tumor location | Surgery2 | Postoperative KPS3 | Radiation dose (cGy) | Systemic treatment | Progression-free survival (months) | Treatment for progression | Overall survival (months) |
|---|---|---|---|---|---|---|---|---|---|---|
1 | 42 F | ATRX loss and mutation; CDKN2A loss, KIAA1549::BRAF and PTPRZ1::MET; MGMT promoter status unknown | Cerebellum | STR | 90 | n/a | n/a | 1.57 | Resection, irradiation | 52.77 |
2 | 38 F | CDKN2A/B loss, ATRX mutation | Temporal | Biopsy-> GTR | 52 | Concurrent TMZ4 | 16.03 | Resection, avastin, optune | LTFU | |
3 | 36 M | ATRX expression retained but mutation detected; NF1 mutation; MGMT promoter status unknown | Temporal | Biopsy | 90 | Unk | Concurrent TMZ + adjuvant TMZ | LTFU | LTFU | LTFU |
4 | 24 F | ATRX loss of expression and mutation; CDKN2A/B loss; NF1 mutation, MGMT promoter unmethylated | Thalamus | Biopsy | 90 | 46 | Concurrent TMZ + adjuvant TMZ | 10.03 | Reirradiation | 15.60 |
5 | 31 F | ATRX loss of expression and mutation; CDKN2A/B loss, NF1 mutation and subclonal BRAF G494V mutation; MGMT promoter status indeterminate | Thalamus | Biopsy-> STR | 80 | 60 | Concurrent TMZ + adjuvant TMZ | 3.43 | Re-irradiation, selumetanib | LTFU |
6 | 47 F | ATRX mutation; CDKN2A loss, FGFR1 mutation, MGMT promoter status indeterminate | Thalamus | Biopsy | Unk | Concurrent TMZ + adjuvant TMZ | 5.40 | Avastin | LTFU | |
7 | 52 F | ATRX mutation; CDKN2A/B loss; MGMT status unknown | Thalamus | Biopsy | 54 | Concurrent TMZ + adjuvant TMZ | n/a | n/a | n/a | |
8 | 62 F | ATRX loss of expression and mutation; FGFR1 mutation, amplification of CDK4 and MDM2, copy number loss of RB1; MGMT promoter unmethylated | Brainstem | GTR | 39 | Concurrent TMZ + adjuvant TMZ | n/a | n/a | n/a | |
9 | 27 M | CDKN2A/B loss, BRAF V600E, MGMT promoter unmethylated | Cerebellum | GTR | 100 | n/a | n/a | 5.23 | Radiation, Dabrafenib, trametinib | n/a |
10 | 42 M | No ATRX mutation; CDKN2A/B loss, NF1 mutation; MGMT promoter methylated | Cerebellum | Biopsy | 60 | Concurrent TMZ | LTFU | n/a | LTFU | |
11 | 31 M | ATRX loss of expression; BRAF V600E; MGMT promoter status indeterminate | Temporal | STR | 80 | Unk | Concurrent TMZ + adjuvant TMZ, Optune | 28.17 | TMZ, LITT, Dabrafenib/trametinib, investigational BRAF inhibitor | LTFU |
12 | 37 M | ATRX loss of expression and mutation; CDKN2A/B loss, KIAA1549::BRAF, TGFBR1 mutation; MGMT promoter methylated | Cerebellum | Biopsy | 90 | n/a | Trametinib | LTFU | LTFU | LTFU |
13 | 53 F | ATRX loss of expression and mutation; CDKN2A/B loss, FGFR1 mutation, MGMT promoter methylated | Thalamus | Biopsy | 90 | n/a5 | n/a5 | n/a5 | n/a | n/a |
14 | 67 M | Retained ATRX expression; RB1 mutation; MGMT promoter methylated | Cerebellum | Biopsy-> STR | 90 | 60 | Adjuvant TMZ | n/a | n/a | n/a |
15 | 59 F | ATRX loss of expression and mutation; CDK2NA/B loss, MGMT promoter unmethylated | Cerebellum | GTR | Unk | Concurrent TMZ + adjuvant TMZ | 2.13 | LTFU | LTFU | |
16 | 50 M | ATRX loss of expression and mutation, NF1 mutation, MGMT promoter unmethylated | Spinal Cord | STR | 80 | 40 | Adjuvant TMZ | 7.73 | Selumetinib | 13.17 |
17 | 43 F | ATRX loss of expression, MGMT promoter unmethylated | Medulla | Biopsy | 70 | 54 | None | 3.17 | Avastin | n/a |
18 | 58 F | Retained ATRX expression; CDKN2A loss, NF1 mutation, TP53 mutation, MGMT promoter unmethylated | Cerebellum | Biopsy | 80 | 60 | Concurrent TMZ | n/a | n/a | n/a |